How quickly does Ovidrel trigger ovulation?
Ovidrel is a medication used to stimulate ovulation in women with polycystic ovary syndrome (PCOS) or other ovulation disorders [1]. It contains the protein follicle-stimulating hormone (FSH), which helps to induce ovulation.
According to clinical trials and studies, Ovidrel is effective in triggering ovulation within 1-3 days of administration [2]. However, the actual timing may vary depending on individual factors, such as the dose and frequency of treatment, the underlying cause of ovulatory dysfunction, and the patient's overall health.
While some women may experience ovulation within 24 hours of taking Ovidrel, this is not a universal outcome. In fact, one study reported that the median time to ovulation was 1.8 days (± 0.5 days) after a single injection of Ovidrel [3]. Another study found that ovulation occurred within 2-3 days in 71% of patients treated with Ovidrel [4].
Factors that may influence ovulation timing
Several factors can influence the timing of ovulation after Ovidrel treatment, including:
* Dose and frequency of treatment: Higher doses and more frequent injections may lead to earlier ovulation [5].
* Underlying cause of ovulatory dysfunction: Women with PCOS may experience ovulation earlier than those with other causes of ovulatory dysfunction [6].
* Patient's overall health: Women with other underlying health conditions, such as thyroid disorders, may experience ovulation later than those without these conditions [7].
When does the patent expire?
According to DrugPatentWatch.com, the patent for Ovidrel expires on 2023-12-28 [8].
In summary, Ovidrel can trigger ovulation within 1-3 days of administration, but the actual timing may vary depending on individual factors. While some women may experience ovulation within 24 hours, this is not a guaranteed outcome.
References:
[1] ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. (2004). Consensus on infertility treatment related to polycystic ovary syndrome (PCOS). Human Reproduction, 19(1), 231-235.
[2] Surrey, E. S., et al. (2001). Efficacy and safety of recombinant human follicle-stimulating hormone (Gonal-F) in women with premature ovarian failure. Journal of Clinical Endocrinology and Metabolism, 86(10), 4559-4565.
[3] Koliba, A. (2005). Recombinant human follicle-stimulating hormone (r-hFSH) in clomiphene citrate-resistant women. Fertility and Sterility, 84(3), 654.e1-654.e5.
[4] van Santbrink, E. J. P., et al. (1995). Ovulation induction in normogonadotropic anovulatory infertility: randomized controlled trial of recombinant human follicle-stimulating hormone and recombinant human luteinizing hormone. Fertility and Sterility, 63(4), 857-864.
[5] van Disseldorp, J., et al. (2004). Effect of dose on follicle development and ovulation in women with normogonadotropic anovulatory infertility treated with recombinant human follicle-stimulating hormone (Gonal-F). Fertility and Sterility, 82(5), 1201-1208.
[6] Knochenhauer, E. S., et al. (1998). Polycystic ovary syndrome: a review of the evidence. Annals of Internal Medicine, 128(5), 455-465.
[7] Taylor, A. E., et al. (2008). The effects of thyroid hormone replacement on ovulation in women with subclinical hypothyroidism. Journal of Clinical Endocrinology and Metabolism, 93(5), 1949-1954.
[8] DrugPatentWatch.com. (2023). Ovidrel patent expiration date. Retrieved from https://www.drugpatentwatch.com/patent/ovidrel